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Time to sustained worsening in the expanded disability status scale as the standard for evaluating the accumulation of disability
has been used as a measure of clinical eﬃcacy in many relapsing-remitting multiple sclerosis (RRMS) clinical trials. However, this
measurement usually requires a large sample and long-term study to demonstrate the treatment eﬀect. Annualized relapse rate or
time to ﬁrst relapse is also widely used as alternative measurements of clinical eﬃcacy. A formal statistical validation of short-term
relapse activity as a surrogate endpoint for long-term sustained progression of disability could potentially permit smaller, shorter,
andlessexpensiveclinicaltrialsinRRMS.Fourstatisticalvalidation/evaluationapproachesconsistentlyshowedthatrelapseactivity
through one year of treatment serves as statistically valid surrogate endpoint for time to sustained progression of disability. The
analysis demonstrates that long-term sustained progression of disability can be predicted by short-term relapse measures with
4 consistent validations of statistical approaches, including a formal statistical hypothesis test. This was demonstrated in a large
phase III trial of natalizumab and showed that the beneﬁcial clinical eﬀect of natalizumab on sustained progression of disability at
2 years in patients with RRMS can be predicted by the total number of relapses at 1 year.
1.Introduction
Multiple sclerosis (MS) is an inﬂammatory disease of the
brain and spinal cord characterized by focal areas of inﬂam-
mation that lead to destruction of the myelin sheath and
varying degrees of axonal injury. The typical inﬂammatory
lesions of MS can occur throughout the central nervous
system (CNS), but certain sites seem particularly vulnerable,
such as the optic nerve, brainstem, spinal cord, and periven-
tricular regions. In approximately 85% of people with MS
the disease begins with relapses and remissions in disease
activity. Recurrent attacks over decades of disease activity
result in accumulating neurologic disability. In MS clinical
trials, the standard for evaluating the accumulation of sus-
tained disability, or the degree of neurologic impairment, is
the EDSS, an overall disability status scale that has steps from
0( n o r m a l )t o1 0( d e a t hd u et oM S )[ 1]. It consists of 8 func-
tional systems, each graded from 0 (normal) to 5 or 6
(maximum impairment), plus evaluation of gait. The limita-
tions of the EDSS scale to assess disability are well known: it
is heavily biased to locomotor function, it has poor sensitiv-
ity to change, especially at certain levels, and has only mod-
erate inter- and intrarater reliability. For these reasons, this
measurement usually requires a large sample size and long-
term (2 to 3 years) study to demonstrate a beneﬁcial treat-
ment eﬀect in clinical trials.
Other measures of disease activity include various MRI
evaluations and measures of MS relapse activity. Because of
theimportanceofthislatterendpointinclinicaltrials,multi-
ple ways of quantifying relapse reductions have been utilized
in previous studies, including ARR [2–7], proportion of re-
lapse free patients [2–7], time to ﬁrst relapse [2–4, 6, 7],
severity of relapses [5–7] ,a n dm e a nn u m b e ro fn e wr e l a p s e s
during the study period [3, 4, 6, 7].
The large sample size and lengthy duration of study re-
quired to use disability progression as the primary outcome2 Neurology Research International
measure have made MS clinical trials operationally challeng-
ing. One goal of MS clinical trial research has been to iden-
tify more cost-eﬀective ways of determining valid clinical
responses to therapeutic interventions. Prior eﬀorts to iden-
tify and validate surrogate markers for clinical disability out-
comes in MS have been disappointing. Part of the diﬃculty
has been the lack of a suﬃcient clinical database for eval-
uating these measures.
Wehaveevaluateddatafromthelargeplacebo-controlled
AFFIRM trial of natalizumab [8] to explore the use of short-
term relapse activity as a surrogate endpoint for longer-term
sustaineddisability.Weshowthattheclinicalbeneﬁcialeﬀect
on sustained progression of disability at 2 years in patients
with RRMS can be predicted by the one-year relapse rate,
using validations of statistical approaches including a formal
statistical hypothesis test.
2.MaterialsandStatisticalMethods
2.1. Patients. Subjects with a diagnosis of RRMS as deﬁned
by McDonald et al. [9], and a baseline EDSS score between
0.0 and 5.0, inclusive, participated in a randomized, double-
blind, placebo-controlled trial of natalizumab. Participants
were between 18 and 50 years of age. Each had a cranial MRI
scandemonstratinglesion(s)consistentwithMSandhadex-
perienced at least one medically documented clinical relapse
within the 12 months prior to randomization.
Of the 942 subjects enrolled in the study with 2:1 ran-
domization, 315 were randomized to receive placebo with a
mean followup of 1.79 years and 627 were randomized to
receive natalizumab with a mean followup of 1.88 years.
Apart from 3 subjects randomized to receive placebo who
withdrewfromthestudypriortoreceivingrandomizedtreat-
ment, all subjects received at least 1 dose of study drug. Infu-
sions of placebo or 300mg natalizumab were scheduled to be
administered every 4 weeks for up to 116 weeks. A total of
856 patients who completed the two-year study and who had
no missing data regarding relapses at the 1-year timepoint
were included in this analysis.
Baseline demography was balanced between the groups.
The expanded disability status scale scores at baseline ranged
from 0 to 6 (median of 2). Four subjects, two in each treat-
ment group, had baseline EDSS scores greater than the upper
limit of 5.0 speciﬁed in the entry criteria of the study.
2.2.ClinicalEﬃcacyOutcomeMeasures. Theprimaryclinical
eﬃcacy endpoint was the time to sustained progression of
disability, as measured by at least a 1.0-point increase in the
EDSS from baseline for patients entering with EDSS ≥ 1.0 or
at least a 1.5 point increase for those with baseline EDSS = 0,
each of which was sustained for 12 weeks. This endpoint
was used to determine whether the treatment was eﬀective
in slowing the progression of disability. The coprimary end-
point in the study was ARR through the ﬁrst year. Conﬁrma-
toryanalysesintheAFFIRMstudy,coveringtheentire2-year
studyperiodincludedARR,annualizedrelapseraterequiring
steroid treatment, time to ﬁrst relapse, and the proportion of
patients who were relapse-free.
Forthecurrentanalysis,weconsideredEDSSprogression
(noted as T) as the true clinical outcome and the total num-
ber of clinical relapses that a patient experienced through the
ﬁrst year as the candidate surrogate marker (noted as S)f o r
EDSS progression.
2.3. Statistical Methodologies for the Validation of Surrogacy.
We assessed the surrogacy of ﬁrst-year relapses for the time
to sustained progression of disability at 2 years by four well-
recognized statisticalapproaches,including thestatisticalhy-
pothesis-testing approach based on the Prentice criteria that
has largely been used in surrogacy validation studies in MS
[10–12] and that was recently applied to a study with similar
aims in IFN-treated patients [13] and three quantiﬁcation
approaches for the eﬀect of the surrogate endpoint.
2.3.1. A Hypothesis Testing Approach Based on the Prentice
Criteria. The Prentice criteria [14] are generally accepted as
thestatisticaldeﬁnitionofasurrogateendpoint.Abiomarker
isconsideredastatisticallyvalidsurrogateendpointifthefol-
lowing four conditions are satisﬁed: (1) the treatment has a
signiﬁcantly beneﬁcial eﬀect on the clinical endpoint, (2) the
treatmenthasasigniﬁcantlybeneﬁcialeﬀectonthesurrogate
endpoint, (3) the clinical endpoint and surrogate endpoint
are signiﬁcantly correlated, and (4) the treatment eﬀect on
the clinical endpoint becomes statistically insigniﬁcant after
adjusting for the surrogate endpoint.
In this paper, T denotes the true clinical endpoint, S de-
notesapotentialsurrogateendpoint,andZ denotesthetreat-
ment group. A biomarker S is considered a surrogate end-
point for a clinical endpoint T under the Prentice criteria if
the triplet (T, S, Z) fulﬁlls the following four conditions:
f(T | Z) / = f(T), (1)
f (S | Z) / = f(S),( 2 )
f(T | S) / = f(T),( 3 )
f (T | S,Z) = f (T | S), (4)
where, for example, f(T | Z) is the conditional distribution
ofthetrueendpointT giventhetreatmentassignmentZ,and
f(T) is the unconditional distribution of the true endpoint
T. When the condition (1) is satisﬁed, the treatment Z has
a signiﬁcant eﬀect on the clinical endpoint T. Therefore, the
ﬁrst three criteria describe the dependence between any two
of the triplet (T, S, Z) and they are preconditions for a bio-
marker to be considered as a candidate surrogate endpoint.
The fourth criterion has been generally recognized as the sta-
tistical deﬁnition of surrogacy, which deﬁnes that the treat-
ment eﬀect on the clinical endpoint becomes statistically
insigniﬁcant when it is adjusted by the surrogate endpoint,
andwewillrefertoitasthePrenticecriterioninthefollowing
sections.
In the natalizumab study, both the time to sustained
disability at 2 years and ARR at 1 year were primary end-
points, and natalizumab was approved based on signifi-
cant treatment eﬀect on these two endpoints, hence the
criterion (1)a n d( 2) are satisﬁed. We will therefore focus onNeurology Research International 3
Table 1: Summary of time to sustained progression of disability at two years as measured by increase in EDSS—ITT population.
Placebo Natalizumab P valuea
Number of subjects randomized 315 (100) 627 (100)
Number of subjects progressed 84 (27) 104 (17)
Time (yr) to progressionb
Mean and 95% CI 1.78 (1.72, 1.84) 1.90 (1.87, 1.94)
Estimated proportion of progression at 2 yearsb 0.29 0.17
Hazard ratio (natalizumab/placebo) and 95% CI 0.58 (0.43, 0.77) <0.001
Note: sustained progression of disability is deﬁned as at least a 1.0-point increase on the EDSS from a baseline EDSS ≥ 1.0 sustained for 12 weeks or at least a
1.5-point increase on the EDSS from a baseline EDSS of 0 sustained for 12 weeks.
a: P value assessing the diﬀerence between the treatment groups, from Cox proportional hazards model, adjusted for baseline EDSS values and age
(<40 versus ≥40).
b: Estimated time to progression and proportion of subjects with progression based on the Kaplan-Meier product limit method.
the veriﬁcation of criteria (3)a n d( 4). The validity of the
thirdcriterionwasveriﬁedbymodelingthetimetosustained
disability by the Cox proportional hazard model with total
number of relapses at 1 year as the only predictor. The ver-
iﬁcation of the fourth criterion is based on modeling the
time to sustained disability by the Cox proportional hazard
regression model with treatment and total number of relaps-
es at 1 year as covariates.
2.3.2. Quantiﬁcation Approaches
Proportion of Treatment Eﬀect Explained. The proportion of
treatment eﬀect explained by surrogate endpoint (PTE) was
proposed by Freedman et al. [15] to quantify how much the
treatment eﬀect on the clinical endpoint is captured by the
surrogate endpoint based on an intuitive interpretation of
the fourth Prentice criterion. PTE is computed as one minus
the ratio of the regression coeﬃcients of the treatment in a
full model with both treatment and surrogate endpoints as
the covariates, and a reduced model with only treatment as
the covariate.
Adjusted Likelihood Reduction Factor. The adjusted likeli-
hood reduction factor (LRFa) was proposed by Alonso et al.
[16] to evaluate the treatment eﬀect via surrogate endpoint
based on the estimation of generalized correlation between
the clinical endpoint and the surrogate endpoint. LRFa is
computed as
LRFa =
1 −exp{−(LRT(Z +S : Z))/n}
1 −exp{−(LRT(Z +S :1 ))/n}
, (5)
where LRT(Z + S : Z) is the likelihood ratio statistic com-
paring the model with both Z and S as the covariates and the
model with only Z as the covariate; LRT(Z + S : 1) is the
likelihood ratio statistic comparing the model with both Z
and S as the covariates and the model with only intercept.
Proportion of Information Gain. The proportion of informa-
tiongained(PIG)bysurrogateendpointwasproposedbyQu
andCase[17]toquantifytheeﬀectofthesurrogateendpoint
via Kullback-Leibler information gain. The PIG is expressed
as the ratio of information gained by the surrogate endpoint
to the information gained by the surrogate endpoint and
treatment together, as computed by
PIG =
LRT(S :1 )
LRT(Z +S :1 )
, (6)
where LRT(S : 1) is the likelihood ratio test statistic com-
paring the model with S as the covariate and the intercept
model; LRT(Z + S : 1) is the likelihood ratio test statistic
comparing the model with both S and Z as the covariates
and the intercept model.
For the hypothesis testing approach, if the treatment
eﬀect becomes insigniﬁcant after adjusting for the candidate
surrogate endpoint, then the candidate surrogate endpoint is
consideredavalidsurrogateendpoint.Forthethreequantiﬁ-
cationapproaches,avaluecloseto1suggestsgoodsurrogacy.
3. Results
3.1. Satisfaction of the First and Second Prentice Criteria. In
the clinical study report of natalizumab, the treatment eﬀect
on the time to sustained progression of disability at 2 years
was statistically signiﬁcant. The Kaplan-Meier estimate of
percentage of subjects progressing by 2 years in the placebo
group was 29% compared to 17% for the group that received
300mg natalizumab. The comparison between the treatment
groupandplacebogroupwasmadeusingaCoxproportional
hazards model adjusting for the baseline EDSS score and age
(<40versus ≥40).Thehazardratioobtainedfromthismodel
was 0.58 (95% CI: 0.43, 0.77) indicating a 42% reduction
in the risk of disability progression following treatment with
natalizumab. The comparison between the treatment group
and placebo group was highly statistically signiﬁcant (P<
0.001; Table 1).
The coprimary endpoint ARR at 1 year was calculated
usingPoissonregressionadjustingforthenumberofrelapses
in the previous year, baseline EDSS, the presence of Gd-
enhancing lesions on T1-weighted MRI, and age. Subjects
were censored at the time at which they added rescue treat-
ment with an available MS treatment. ARR at 1-year for the
placebo group was 0.805 (95% CI: 0.669, 0.969) compared
to 0.261 (95% CI: 0.211, 0.323) for the group that received
300mg natalizumab. This diﬀerence of 0.544 represents a4 Neurology Research International
Table 2: Annualized relapse rate—ITT population—one-year analysis.
Placebo Natalizumab Rate Ratio (95% CI) and P value (a)
Number of subjects randomized 315 (100) 627 (100)
Number of subjects with a relapse 135 (43) 132 (21)
Number of relapsesb
0 180 (57) 495 (79)
1 76 (24) 111 (18)
2 42 (13) 17 (3)
38 ( 3 ) 4 ( <1)
≥49 ( 3 ) 0
Total number of relapses 224 157
Total subject-years followed 320.1 652.6
Unadjusted annualized relapse ratec 0.700 0.241
Adjusted annualized relapse rate 0.805 0.261 0.325
(95% CI)a (0.669, 0.969) (0.211, 0.323) (0.256, 0.412)
<0.001
Subject relapse rated
Mean 0.778 0.262
Median 0.000 0.000
Note: the analysis includes relapses and time on the study up to the time that alternative MS medication is added.
a: From Poisson regression, adjusted for the number of relapses in the one year prior to study entry, baseline EDSS (≤3.5 versus >3.5), presence of Gd lesions
(present versus absent), and age (<40 versus ≥40).
b: Numbers in parentheses are percentages.
c: The total number of relapses that occurred during the study divided by the total number of subject-years followed in the study.
d: The number of relapses for each subject divided by the number of years followed in the study for that subject. Mean and median across all subjects are
presented.
68% decrease in the ARR following treatment with 300mg
natalizumab versus placebo and was highly statistically sig-
niﬁcant (P<0.001; Table 2). Therefore, both the ﬁrst and
second Prentice criteria are satisﬁed.
3.2. Satisfaction of the Third Prentice Criterion. To validate
the satisfaction of the third Prentice criterion, we deﬁned the
optimal response with 0 relapse at 1 year and suboptimal
responsewithatleastonerelapseat1yearandtestedwhether
the short-term relapse is a predictor for the long-term EDSS.
The Wilcoxon rank sum test shows that the relapse at 1 year
is a strong predictor for the EDSS at 2 years (P<0.0001;
Table 3). The Cox proportional hazard model also shows a
strong association between ARR at 1 year and the EDSS at 2
years (P<0.0001). The hazard ratio in Table 4 shows that
a patient with one more relapse during the ﬁrst year is 2.26-
timesmorelikelytodevelopsustainedprogressionofdisabil-
itycomparedtoapatientwithonelessrelapseduringtheﬁrst
year. Thus, the third Prentice criterion is satisﬁed.
3.3. Assessing the Satisfaction of the Fourth Prentice Criterion.
In the patient sample that entered the current analysis, based
on the hypothesis testing approach, the Cox proportional
hazard model shows that the treatment eﬀect on EDSS at 2
years is statistically signiﬁcant without adjusting for relapses
(HR = 0.61, P = 0.0011) but is not statistically signiﬁcant
with adjusting for relapses (HR = 0.91, P = 0.5486), which
Table 3: EDSS score at 2 years in patients with optimal (0 relapse)
or suboptimal responses (≥1 relapses) at 1 year—ITT population.
Optimal Suboptimal P valuea
EDSS score
n 637 218
Mean (SD) 2.093 (1.283) 3.016 (1.605)
Median 2.0 3.0 <0.0001
Range 0, 6.5 0, 8.0
a: P v a l u ei sf r o mW i l c o x o nr a n ks u mt e s t .
suggests that treatment eﬀect-related reduction in short-
term relapse signiﬁcantly delayed the long-term disability
progression in RRMS patients. Thus the fourth Prentice cri-
terion is also satisﬁed.
3.4. Conclusions. In practice, while compelling, the validity
criterionisnoteasilycheckedforsurrogacy.ThePrenticecri-
teriaaremuchmoreeasilyveriﬁedthanthevaliditycriterion,
yetarepurportedtoimplythevaliditycriterion.Ouranalysis
shows that the four Prentice criteria are satisﬁed and the
resultssuggestthatthe1yearrelapserateisastatisticallyvalid
surrogate endpoint for progression of disability at 2 years.
Furthermore, all three quantiﬁcation approaches give a value
close to 1, suggesting that the surrogacy is good and that the
results are consistent with the Prentice criteria. Therefore,
all four approaches support short-term relapse rate as aNeurology Research International 5
Table 4: Validation of 1-year relapses as the surrogate endpoint for EDSS at 2 years.
Hypothesis testing approach∗
Association between
relapse and EDSS
Treatment eﬀect on EDSS
w/o adjusting relapse
Treatment eﬀect on EDSS
with adjusting relapse
Quantiﬁcation approaches
True
endpoint
Surrogate
endpoint HR P value HR P value HR P value PTE LRFa PIG
EDSS at
2-yr
Relapse at
1-yr 2.26 <0.0001 0.61 0.0011 0.91 0.5486 0.801 0.892 0.995
∗: All Cox proportional hazards model for the time to sustained disability are adjusted for the baseline EDSS score and age group (<40 versus ≥40).
∗Analysis was restricted to the patients who had no missing values of the endpoints.
surrogate endpoint for long-term sustained progression of
disability in RRMS patients. In other words, a majority of
the treatment eﬀect on long-term sustained progression of
disability can be captured by short-term relapses, suggesting
that relapses over the short term may be a reﬂection of the
same pathophysiologic process that is leading to disability
progression.
4. Discussion
Clinical trials of new immune modulators as disease modi-
fying agents in MS have become larger and more expensive
as the standards of care worldwide have included early and
sustained treatment with existing therapies. Thus, control
groups consisting of those receiving placebo alone have
become both impractical and unethical in most clinical trial
situations involving RRMS. Resultant clinical trial designs
(e.g., add-on or head-to-head studies) have required larger
numbers of subjects and/or longer observation periods, par-
ticularly when evaluating disability progression as an out-
come measure. Thus, the identiﬁcation of surrogate markers
thatmay substituteformeasuresofdisability progression has
become an important goal in MS clinical trial research.
Most prior eﬀorts to identify and validate surrogate
markers for clinical disability outcomes in MS have been dis-
appointing. Part of the diﬃculty has been the lack of a suf-
ﬁcient clinical database for evaluating these measures. The
goal of the current study is to build a scientiﬁc link between
long-term sustained progression of disability and short-term
clinical relapses, which is operationally applicable in order to
avoid large long-term studies when it is practical to do so.
Wehaveevaluateddatafromthelargeplacebo-controlled
AFFIRMtrialofnatalizumabtoexploretheuseofshort-term
relapse activity as a surrogate endpoint for long-term sus-
tained disability. We show that the clinically beneﬁcial eﬀect
on sustained progression of disability at 2 years in patients
with RRMS is predicted by the one-year relapse rate using
four consistent validations of the statistical approaches.
All four Prentice criteria were satisﬁed in this analysis.
The criteria (1)a n d( 2) were satisﬁed in the natalizumab
study, as the treatment eﬀects on both the time to sustained
disability at 2 years and ARR at 1 year were statistically sig-
nificant. The criterion (3) was satisﬁed, as both the Wilcoxon
rank sum test and the Cox proportional hazard model
showed strong associations between ARR at 1 year and the
EDSS at 2 years. The criterion (4) was satisﬁed, as the Cox
proportional hazard model showed that the treatment eﬀect
on EDSS at 2 years is statistically signiﬁcant without adjust-
ingforrelapsesbutisnotstatisticallysigniﬁcantwhenadjust-
ing for relapses.
Furthermore, three quantiﬁcation approaches supported
the conclusion that a majority of the treatment eﬀect on
long-termsustainedprogressionofdisabilitycanbecaptured
by short-term relapses. The PTE, LRFa, and PIG evaluations
all gave values close to 1, suggesting that the surrogacy is
good and that the results are consistent with the Prentice cri-
teria. Therefore, all four approaches support measurement
of short-term relapses as a surrogate endpoint for long-term
sustained progression of disability in RRMS patients.
It is possible that the responsiveness of this measure is
speciﬁc for only some, but not all, treatment modalities.
Natalizumab, ﬁngolimod, and some of the interferons have
demonstrated eﬃcacy using outcome measures for both
relapse rate and disability progression. However, glatiramer
acetate has shown eﬃcacy in reducing relapse rate but failed
to demonstrate slowing of disability progression over a two-
year period. Recently Sormani et al. [18] evaluated the link
between responsiveness of relapse rate or MRI characteristics
and responsiveness of disability progression using a pooled
database consisting of data from 19 clinical trials of various
therapeutic agents in RRMS. Eleven of these trials involved
interferon beta, two involved natalizumab, and one trial
each involved mitoxantrone, IVIg, alemtuzumab, cladribine,
and azathioprine. Only two involved glatiramer acetate. It is
quitelikelythat,becausethedatainvolvingglatirameracetate
were derived from too small a percentage of the total to be
reﬂected in the ﬁnal outcome, those data were overwhelmed
by data from trials involving agents that beneﬁcially aﬀected
both relapse rate and disability progression. In any case, it is
possible that the methodology described in the current re-
port and in the report by Sormani et al. [18]w i l ln o tb ea p -
plicabletothestudyofallproposeddiseasemodifyingagents.
In conclusion, the data reported here, together with the
published study of Sormani et al., strongly suggest that in
studies of therapeutic agents that favorably aﬀect both re-
lapse rate and disability progression in RRMS, measurement
of relapse rate serves as a reliable surrogate marker for dis-
ability progression. Data from the pivotal trial of glatiramer
acetate in RRMS indicate that this relationship may not be
evident for all therapeutic modalities, however. This suggests
that, while disability progression should continue to be
directly measured in pivotal phase III trials in RRMS, once6 Neurology Research International
a therapy has been shown to beneﬁt both relapse rate and
disability progression, subsequent phase 4 trials may be able
to utilize measures of relapse rate as a reliable surrogate for
disability progression.
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